https://www.selleckchem.com/pr....oducts/vevorisertib-
Coronavirus-like particles (CoVLP) that are produced in plants and display the prefusion spike glycoprotein of the original strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are combined with an adjuvant (Adjuvant System 03 [AS03]) to form the candidate vaccine. In this phase 3, multinational, randomized, placebo-controlled trial conducted at 85 centers, we assigned adults (≥18 years of age) in a 11 ratio to receive two intramuscular injections of the CoVLP+AS03 vaccine or placebo 21 days apart
Like
Comment
Share
